15-year cause specific and all-cause survival following brachytherapy for prostate cancer: negative impact of long-term hormonal therapy.

[1]  M. Kattan,et al.  Mortality after prostate cancer treatment with radical prostatectomy, external-beam radiation therapy, or brachytherapy in men without comorbidity. , 2013, European urology.

[2]  Michael Goodman,et al.  Effect of Age, Tumor Risk, and Comorbidity on Competing Risks for Survival in a U.S. Population–Based Cohort of Men With Prostate Cancer , 2013, Annals of Internal Medicine.

[3]  J. Stanford,et al.  Mortality after radical prostatectomy or external beam radiotherapy for localized prostate cancer. , 2013, Journal of the National Cancer Institute.

[4]  B. Trock,et al.  The impact of anatomical radical retropubic prostatectomy on cancer control: the 30-year anniversary. , 2012, The Journal of urology.

[5]  A. Dicker,et al.  The impact of brachytherapy on prostate cancer-specific mortality for definitive radiation therapy of high-grade prostate cancer: a population-based analysis. , 2012, International journal of radiation oncology, biology, physics.

[6]  Hiroyuki Takahashi,et al.  Tri-Modality therapy with I-125 brachytherapy, external beam radiation therapy, and short- or long-term hormone therapy for high-risk localized prostate cancer (TRIP): study protocol for a phase III, multicenter, randomized, controlled trial , 2012, BMC Cancer.

[7]  A. Shalhav,et al.  Cause-specific mortality following radical prostatectomy , 2011, Prostate Cancer and Prostatic Diseases.

[8]  J. Blasko,et al.  Fifteen-year biochemical relapse-free survival, cause-specific survival, and overall survival following I(125) prostate brachytherapy in clinically localized prostate cancer: Seattle experience. , 2011, International journal of radiation oncology, biology, physics.

[9]  A. D'Amico,et al.  Mortality in men with localized prostate cancer treated with brachytherapy with or without neoadjuvant hormone therapy , 2010, Cancer.

[10]  Liang Cheng,et al.  Radical prostatectomy as initial monotherapy for patients with pathologically confirmed high‐grade prostate cancer , 2009, BJU international.

[11]  M. Kattan,et al.  Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7-10 prostate cancer treated with permanent prostate brachytherapy. , 2009, International journal of radiation oncology, biology, physics.

[12]  M. Oefelein.  Androgen suppression therapy and prostate cancer , 2008, Cancer.

[13]  A. Renshaw,et al.  Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. , 2008, JAMA.

[14]  A. D'Amico,et al.  Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. , 2007, Journal of the National Cancer Institute.

[15]  R. Stock,et al.  The effect of brachytherapy, external beam irradiation and hormonal therapy on prostate volume. , 2007, The Journal of urology.

[16]  P. Carroll,et al.  20-year outcomes following conservative management of clinically localized prostate cancer , 2005 .

[17]  Barry S Rosenstein,et al.  Biologically effective dose values for prostate brachytherapy: effects on PSA failure and posttreatment biopsy results. , 2005, International journal of radiation oncology, biology, physics.

[18]  D. Beyer,et al.  Impact of short course hormonal therapy on overall and cancer specific survival after permanent prostate brachytherapy. , 2005, International journal of radiation oncology, biology, physics.

[19]  Jaime Pujadas Oláno,et al.  Natural history of early localized prostate cancer. , 2004, JAMA.

[20]  J. Manola,et al.  6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. , 2004, JAMA.

[21]  A. Hanlon,et al.  The relationship of increasing radiotherapy dose to reduced distant metastases and mortality in men with prostate cancer , 2004, Cancer.

[22]  A. Hanlon,et al.  Does short-term androgen deprivation substitute for radiation dose in the treatment of high-risk prostate cancer? , 2002, International journal of radiation oncology, biology, physics.

[23]  Jacques Bernier,et al.  Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial , 2002, The Lancet.

[24]  D. Grignon,et al.  Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. , 2001, International journal of radiation oncology, biology, physics.

[25]  A. Partin,et al.  Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. , 2001, The Urologic clinics of North America.

[26]  B. Chauvet,et al.  [Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin]. , 1998, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

[27]  R. Stock,et al.  A modified technique allowing interactive ultrasound-guided three-dimensional transperineal prostate implantation. , 1995, International journal of radiation oncology, biology, physics.

[28]  C. Lawton.  Fifteen-year biochemical relapse-free survival, cause-specific survival, and overall survival following I125 prostate brachytherapy in clinically localized prostate cancers: Seattle experience , 2012 .

[29]  R. Stock,et al.  Comparison of intraoperative dosimetric implant representation with postimplant dosimetry in patients receiving prostate brachytherapy. , 2003, Brachytherapy.

[30]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.